National Comprehensive Cancer Network 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Proton Therapy Controls Common Pediatric Brain Tumor with Fewer Long-Term Side Effects (Massachusetts General Hospital Cancer Center)
The use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology. The paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 29, 2016 Category: Cancer & Oncology Source Type: news
Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care with Big Data
Thirty-two researchers from 14 institutions joined forces to identify personalized treatment options for a patient with metastatic triple-negative breast cancer.
C. Anthony Blau, MD
FORT WASHINGTON, PA - An unprecedented approach to clinical research, documented in the January issue of JNCCN - Journal of the National Comprehensive Cancer Network, brought together 32 researchers from 14 different institutions, including community and academic cancer centers, universiti... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 29, 2016 Category: Cancer & Oncology Source Type: news
NCCN Publishes New Clinical Practice Guidelines for Vulvar Cancer
The new NCCN Guidelines for Vulvar Cancer are the most comprehensive and up-to-date clinical guidelines available to clinicians today.
FORT WASHINGTON, PA - It is estimated that more than 5,000 cases of Vulvar Cancer were diagnosed in the United States in 2015, and approximately 1,000 women died from the diseasei. In order to provide comprehensive, up-to-date clinical treatment guidelines for this rare cancer, the National Comprehensive Cancer Network® (NCCN®), an alliance of 26 of the nation... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 28, 2016 Category: Cancer & Oncology Source Type: news
Cancer Centers Urge Increase in HPV Vaccinations
The top cancer centers in the U.S. jointly called for an increase in vaccination against the human papilloma virus, or HPV, saying low uptake of the three-shot regimens amounts to a 'public health threat' and a major missed opportunity to prevent a variety of potentially lethal malignancies.
All 26 NCCN Member Institutions were represented within the 69 total NCI-designated cancer centers issuing the statement.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 27, 2016 Category: Cancer & Oncology Source Type: news
Smokers Who Quit More Than 15 Years Ago Need Screening
Expanding lung cancer screening to include people who quit smoking more than 15 years ago could detect more cases and further reduce associated mortality, according to a study by Mayo Clinic researchers published in the Journal of Thoracic Oncology. Mayo Clinic Cancer Center is one of the 26 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 26, 2016 Category: Cancer & Oncology Source Type: news
Smoking Lowers Breast Cancer Survival, Study Finds
Women diagnosed with breast cancer who continue to smoke cigarettes are less likely to survive than those who never smoked or those who quit, new research finds. The study was led by researchers at UCSF Helen Diller Family Comprehensive Cancer Center-one of the 26 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 26, 2016 Category: Cancer & Oncology Source Type: news
Survival Period for Esophageal Cancer Is Tied to Race and Income
African-American patients with esophageal cancer survive fewer months after diagnosis than white patients, but only if they also have low incomes, according to a new study from Duke Health researchers. Duke Cancer Institute is one of the 26 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 26, 2016 Category: Cancer & Oncology Source Type: news
Nivolumab Combined with Radiation Therapy May Be New Treatment Option for Patients with Melanoma Brain Metastases, Say Moffitt Cancer Center Researchers
President Jimmy Carter's battle with metastatic melanoma to the brain has placed increased attention on management of this disease. President Carter was treated with focused stereotactic radiation to the brain and anti-PD-1 therapy. Researchers at Moffitt Cancer Center recently reported the first series of patients treated with this combined modality approach. They found that radiation therapy combined with the immune-targeting drug nivolumab in melanoma patients with brain metastases is safe an... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 26, 2016 Category: Cancer & Oncology Source Type: news
Targeted Axillary Dissection of Lymph Nodes after Chemotherapy Improves Staging Accuracy of Node-Positive Breast Cancer Patients
A new procedure developed by surgeons at The University of Texas MD Anderson Cancer Center improves the accuracy of axillary staging and pathologic evaluation in clinically node-positive breast cancer, and reduces the need for a more invasive procedure with debilitating complications. The University of Texas MD Anderson Cancer Center is one of the 26 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 25, 2016 Category: Cancer & Oncology Source Type: news
NCCN Awards Research Grants to Five Investigators to Study Effectiveness of Enzalutamide in Various Cancers
The NCCN Oncology Research Program has awarded five research grants to investigate the effectiveness of enzalutamide in mantle cell lymphoma and endometrial, hepatocellular, and prostate cancers.
FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded five grants to investigators to evaluate and define the pre-clinical and clinical effectiveness of enzalutamide in mantle cell lymphoma and endometrial, hepatocellular, and prostate ca... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 15, 2016 Category: Cancer & Oncology Source Type: news
A Statement from NCCN in Support of a Moonshot to Cure Cancer
NCCN Supports President Obama and Vice President Biden in their Moonshot to Cure Cancer Initiative
The National Comprehensive Cancer Network® (NCCN®) applauds and supports the urgency of President Obama and Vice President Biden's Moonshot Initiative to Cure Cancer throughout the world, announced Tuesday during the State of the Union Address and outlined in a statement from the Vice President.
'Vice President Biden's call to leading cancer centers to break down silos and reach unprecedent... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 13, 2016 Category: Cancer & Oncology Source Type: news
NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic Malignancies
The NCCN Oncology Research Program has awarded three research grants to investigate the safety and effectiveness of volasertib in hematologic malignancies.
FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded three grants to investigators from NCCN Member Institutions to scientifically evaluate and define the safety and clinical effectiveness of the investigational compound volasertib in the treatment of hematologic malignancies.... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 13, 2016 Category: Cancer & Oncology Source Type: news
NCCN Awarded $2 Million in Research Funding from Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers
The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to facilitate studies of bavituximab in various cancers.
FORT WASHINGTON, PA -The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to study bavituximab, a first-in-class treatment approach for various cancers.
'NCCN is very pleased to collaborate with Peregrine Pharmaceuticals on t... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 12, 2016 Category: Cancer & Oncology Source Type: news
Experimental Drug is First Targeted Therapy to Improve Survival in Certain High-Risk AML Patients, Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center
Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Richard Stone, MD, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.
Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Ho... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 8, 2015 Category: Cancer & Oncology Source Type: news
‘Purity’ Of Tumor Samples May Significantly Bias Genomic Analyses, UCSF Helen Diller Family Comprehensive Cancer Center
A new study by UC San Francisco scientists shows that the proportion of normal cells, especially immune cells, intermixed with cancerous cells in a given tissue sample may significantly skew the results of genetic analyses and other tests performed both by researchers and by physicians selecting precision therapies.
UCSF Helen Diller Family Comprehensive Cancer Center is one of the 26 NCCN Member Institutions.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 4, 2015 Category: Cancer & Oncology Source Type: news
